Patient-derived xenograft models for oncology drug discovery

发表时间：2015-11-24 浏览次数：1052次

引用：

Li G. Patient-derived xenograft models for oncology drug discovery. J Cancer Met

关键词：

作者：

Gang Li

作者单位：

Ignyta Inc., San Diego, CA 92121, USA

出版年份：

2015

期刊页数：

8-15

收录者：

其他外文数据库

摘要：

The success of targeted therapies for cancer patients rests on three major components: the right target(s), the right drug and drug combination, and the right patient population. Although much progress has been made in understanding the mechanism of disease and in refining pharmaceutical properties of therapeutic agents, the attrition rates between target discovery and drug marketing approval have been high, especially in oncology. One of the main reasons underlying this undesirable statistics is believed to be the lack of predictive power of the model systems used in the preclinical setting. Several strategies have been employed with the aim of improving the predictive value of the preclinical studies, such as incorporating genomic profiling and molecular segmentation into model selection, and enhancing the development and application of patient-derived xenograft models even during early stage of drug discovery. This brief review will summarize some of the recent concept and practice in incorporating patient-derived models into all stages of drug discovery process, from target to clinical development.

阅读全文